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Background and objectives: Routine electroencephalography (rEEG) remains central in the 
prognosis of seizure recurrence among individuals with a First Single Unprovoked seizure (FSUS). 
Furthermore, it is well-established that the presence of epileptiform discharge (ED) in the EEG 
increases the risk of further seizures among individuals with FSUS up to 3 times compared with 
individuals without such EEG changes. However, the rEEG has low sensitivity, leaving patients 
and clinicians without a fast and accurate tool for the prognosis of further seizures. This study aims 
to determine and compare the discriminative power, clinical predictive value, and global 
diagnostic accuracy of the ambulatory EEG compared with the first rEEG and second rEEG. This 
study also aims to determine risk factors for further seizures among individuals with FSUS, 
including ED in the ambulatory EEG. 
Methods: The study used a prospective cohort design with a total of 100 individuals with FSUS 
who underwent three modalities of EEG (first rEEG, second rEEG and Ambulatory EEG) and who 
were followed up for one year period. All the required information was available in this dataset, 
and further seizures were prospectively recorded. The three EEG (first, second rEEGs and 
ambulatory EEG) were interpreted by licensed neurologists recognized by the Royal College of 
Physicians and Surgeons of Canada and fully accredited by the Canadian Society of Clinical 
Neurophysiologists. Diagnosis of epilepsy was made based on clinical, neurophysiology and 
imaging tests following the definition of epilepsy by the International League Against Epilepsy 
2014. Receiver-operating-characteristic (ROC) analysis was used to evaluate the results. Also, 
table-life and survival analysis were used to determine the risk for further seizures during the 52 
weeks follow-up period.  
iii 
Results: We found that the ambulatory EEG’s diagnostic accuracy was better than the first and 
second EEG (0.79 vs. 0.51 and 0.54, respectively) in the population. Age group was a confounder 
in the association between seizure recurrence at 52 weeks and the presence of ED in the ambulatory 
EEG. The presence of ED in the ambulatory EEG increased the risk of seizure recurrence among 
individuals with FSUS 3.2 times when adjusted for use of antiseizure medication (ASM) and age 
group. Finally, other risk factors modifying the association between further seizures and the 
presence of ED in the ambulatory EEG included age group of >60 years (HR: 0.27 95%CI: 
0.10,0.74) and the use of ASM (HR: 12.9, 95%CI: 5.6, 29.3). 
Conclusions: The overall diagnostic accuracy of the ambulatory EEG as a means of detecting ED 
among individuals with FSUS is better than the first and second rEEG. Furthermore, ED in the 
ambulatory EEG is a significant risk factor predicting further seizures after a single unprovoked 
seizure after adjusting for the use of ASM and age group. 
Significance: This study advanced our knowledge about the use of ambulatory EEG as an ancillary 
tool for predicting further seizures after FSUS and established that the presence of epileptiform 
activity in the ambulatory EEG is a risk factor for further seizures after adjusting for use of ASM 
and age group. The use of ambulatory EEG may reduce diagnostic errors and is also low-cost and 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Unprovoked epileptic seizures are common, affecting approximately 8% of the population 
in their lifetime. However, only 30% of the patients who present with a first single unprovoked 
seizure (FSUS) will have a seizure recurrence (i.e., epilepsy) in the next one to two years (1). 
The FSUS is a powerful event for patients with profound life-altering effects such as a 
driver’s license restriction, unemployment, injuries, and accidents. Furthermore, the uncertainty 
about the seizure recurrence carries a significant social and psychological burden for patients and 
their families. 
For the physician evaluating patients with SUS, this situation merits close scrutiny as 
he/she must decide if the SUS was a truly epileptic seizure or not or whether the patient is at high 
risk for seizure recurrence or not, and must ultimately establish the diagnosis of epilepsy and 
initiate treatment with antiseizure medication (ASM), or not (2).  
To establish the diagnosis of SUS, the physician must start with a rigorous clinical 
evaluation emphasizing conventional risk factors for seizure recurrence such as a family history 
of seizures, personal account of febrile seizures, head trauma and brain infections, among others. 
The American Academy of Neurology and American Epilepsy Society guidelines 2015 also 
recommend the use of tools such as Magnetic Resonance Imaging (MRI) and routine 
electroencephalogram (EEG) (3).  
The routine EEG is a neurophysiological test proven beneficial in the prognostic 
determination of the likely seizure recurrence. If abnormalities on the routine EEG are found, the 
risk of seizure recurrence increases 2.1 times. However, the routine EEG has its limitations, as its 
accuracy to detect abnormalities after a first unprovoked seizure only has a sensitivity of 17% and 




finding epileptiform discharges (ED) in the routine EEG (rEEG) in single unprovoked seizures 
(SUS), such as early recording (up to 72hrs) relative to the index event. Also crucial in increased 
accuracy of the EEG is the inclusion of sleep deprivation, the use of serial EEG studies, and 
prolonged recordings (5).  
Ambulatory EEG is a monitoring modality that allows the recording of continuous EEG 
for 24 hours at home, including the patient's sleep cycle (6). The use of ambulatory EEG has 
resulted in a higher rate of detection of abnormalities compared with the rEEG (6). 
Only one study compares the ambulatory EEG with an EEG using sleep deprivation in 
detecting epileptiform discharges in patients with single unprovoked seizures (7). In this study, 
the authors examined a group of patients receiving only an ambulatory EEG and compared their 
outcomes with another group of patients receiving a sleep-deprived EEG. After a year following 
the FSUS, the diagnosis of epilepsy was made. The authors concluded that the diagnostic accuracy 
was similar between both modalities. However, the methodology had flaws as it was a 
retrospective study, and the two tests were performed in different subjects who may not have been 
fully comparable. Therefore, a study evaluating the ambulatory EEG in patients with single 
unprovoked seizures and its relationship with recurrence is needed. 
1.2 Statement of the problem 
On average, 1 in 10 people will have a single epileptic seizure in their lifetime. 
Furthermore, the presence of a single epileptic seizure has a profound physical, socio-economical, 
and psychological impact on an individual and his/her family. The challenges for the attending 
clinician are to find the possible etiology of the seizure and forecast the recurrance risk with the 
use of clinical evaluation and diagnostic tools such as a routine EEG, which with the presence of 




of seizures (3). While highly specific, the routine EEG's sensitivity to detect ED after FSUS ranges 
between 17 to 23% (4,8). An evaluation of ambulatory EEG for the detection of ED and prognostic 
was developed to respond to the need for a better diagnostic and prognostic tool to assess patients 
presenting with FSUS. The ambulatory EEG has shown an excellent diagnostic yield for 
diagnosing, classifying and managing individuals with epilepsy (9). However, there is limited 
evaluation of the ambulatory EEG in the setting of FSUS. Therefore, a rigorous study evaluating 
the ambulatory EEG in patients with FSUSs and its relationship with recurrence is needed. 
1.3 Purposes 
The first main purpose of this study was to estimate the discriminative power (sensitivity, 
specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), and clinical 
predictive value (Likelihood Ratios (LR)) of the ambulatory EEG, the first routine EEG (rEEG), 
and a second rEEG to detect epileptiform discharges (ED) in adult patients with a first single 
unprovoked seizure (FSUS) who present to the Single Seizure Clinic at Royal University Hospital 
in Saskatoon, SK. Canada. This purpose also included the comparison of the internal validities 
within the three modalities of EEGs.  
The second primary purpose of this study was to estimate the risk factors of further seizures 
after FSUS and define the ambulatory EEG's utility in predicting seizure recurrence after one-year 
follow-up.  
Improving the accuracy of ED detection and evaluating seizure recurrence with the 
ambulatory EEG in patients with a FSUS will assist the physician in initiating timely and accurate 
treatment and decreasing the uncertainty, adverse social effects, and ultimately harm for these 




1.4 Research questions and hypotheses 
This study investigated the following four research questions and respective hypotheses.  
1.4.1 Question 1  
What is the discriminative power (sensitivity, specificity, PPV, NPV) and the clinical 
predictive value (LR) of the ambulatory EEG for detecting ED in individuals presenting with a 
FSUS at the Single Seizure Clinic (SSC) at Royal University Hospital in Saskatoon, SK, Canada.  
Hypothesis: The ambulatory EEG's discriminative power to detect ED in patients who 
present with FSUS will be comparable to measures reported in the literature for ambulatory EEG 
and epilepsy (within the range of 75-80%). 
 
1.4.2 Question 2 
Is there better discriminative power and clinical predictive value of ambulatory EEG than 
first and second routine EEGs (rEEGs) in patients presenting with a FSUS? 
Hypothesis: The sensitivity, PPV, and LR for detecting an ED will be better with 
ambulatory EEG in patients presenting with a FSUS than the first rEEG and second rEEG. 
1.4.3 Question 3 
What are the variables associated with seizure recurrence at 52 weeks (one year) of follow-
up in patients that present with a FSUS? 
Hypothesis: The likelihood of seizure recurrence after 52 weeks (one year) of follow-up 
in a patient that presents with a FSUS will likely be approximately more than 50%. Also crucial 
to one-year seizure recurrence will be age, history of brain lesions, stroke and psychiatric 




1.4.4 Question 4 
Is the presence of ED in the ambulatory EEG a risk factor for seizure recurrence during 52 
weeks (one-year) follow-up after a FSUS? 
Hypothesis: The presence of ED in the ambulatory EEG will be a predictor of seizure 
recurrence within a year's follow-up. 
1. 5 Organization of this Thesis 
The content of this thesis is organized into six chapters. 
• Chapter 1- The introduction sets the stage for the current evaluation of the first 
Single Unprovoked Seizure together with its evaluation tools. The 
BACKGROUND segment offers a general view of the definition of FSUS and 
briefly summarizes the problems with the current diagnostic test used. 
STATEMENT OF THE PROBLEM identifies the problem with the present use of 
the routine EEG in assessing the FSUS. PURPOSE describes concisely what this 
research is trying to achieve, laying out in RESEARCH QUESTIONS more 
specifically our questions of interest. 
• Chapter 2-The review further examines the definitions of FSUS (OVERVIEW), 
the EPIDEMIOLOGY and PROGNOSTIC OUTCOME of the FSUS. This chapter 
also describes the current state of the diagnostic approach to the FSUS and the 
advantages and disadvantages of the use of different modalities of the 
electroencephalogram EEG. 
• Chapter 3-Theoretical Perspectives introduce the three fundamental theories that 





• Chapter 4- METHODS presents particular procedures that were undertaken in this 
research. In the STUDY DESIGN, we describe the STUDY POPULATION where 
the cohort originated, the process whereby patients were invited to the study, the 
standard protocol in the evaluation of FSUS (SEIZURE PROTOCOL and 
CLINICAL DIAGNOSIS) and the use of the gold standard (EEG) as well as the 
interventions (second EEG and Ambulatory EEG) to be compared. In this chapter 
we also present the inclusion, exclusion criteria, and the outcomes measured. 
Lastly, the ETHICAL CONSIDERATIONS and the ANALYSIS performed for 
each purpose were described. 
• Chapter 5-Results, presents the findings of the study based upon the information 
gathered after the use of the methodology in Chapter 4. In the POPULATION, we 
describe the cohort obtained followed by the times between each study (WATING 
TIMES) and the DESCRIMINATIVE POWER and CLINICAL PREDICTIVE 
results VALUE of diagnostic tests. Finally, in this chapter, the results of the 
SEIZURE RECURRENCE AND ASSOCIATED RISK FACTORS, tables and 
figures were added. 
• Chapter 6- Discussion, conclusions and recommendations present the results 
compared with previous studies in EEG and seizure recurrence after FSUS. It 






CHAPTER 2: LITERATURE REVIEW 
2.1 First epileptic seizure: an overview 
An epileptic seizure is a “transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain” (10). Epileptic seizures are further 
classified as provoked and unprovoked seizures. Provoked seizures are the result of an insult or 
metabolic or toxic disturbance of the brain. Some factors that may precipitate provoked seizures 
include fever,  acute traumatic brain injury, excessive alcohol intake, withdrawal from alcohol and 
drugs, hypoglycemia, electrolyte disturbances, acute CNS infections, acute ischemic stroke, 
intracranial hemorrhage, and pro-convulsive drugs (such as clozapine, maprotiline, tramadol, 
theophylline, baclofen) (11). Furthermore, individuals experiencing a first provoked epileptic 
seizure are nine times more likely to die within 30 days after the presentation but are 80% less 
likely to present with a subsequent unprovoked seizure(12). 
On the other hand, unprovoked epileptic seizures are seizures without identified proximal 
precipitants (13). Individuals who experience a first unprovoked epileptic seizure have a 65% 
higher risk of subsequent unprovoked seizures than those who present with a provoked epileptic 
seizure (12).  
The presence of subsequent unprovoked seizures is vital due to the implications of the 
eventual diagnosis of epilepsy. Briefly, the diagnosis of epilepsy is based on (14) 
1. At least two unprovoked seizures occurring >24 h apart.  
2. One unprovoked seizure with additional features accompanied by circumstances 




electroencephalogram (EEG) study or stroke lesion in an imaging study such as Magnetic 
Resonance Imaging (MRI) or Computed Tomography (CT)).  
3. Diagnosis of an epilepsy syndrome such as Dravet’s syndrome, childhood absence 
epilepsy, or juvenile myoclonic epilepsy. 
The development of potential subsequent unprovoked seizures or a recent diagnosis of 
epilepsy has significant medical, social, and emotional consequences, most notably on immediate 
driving restrictions. Driving restriction is one of the most critical outcomes among adult patients, 
as it has a significant impact on the lifestyle, employment, and freedom of the patient and his/her 
family. Driving restrictions are generally imposed after the first seizure. Potential loss of 
consciousness during driving can result in serious risks, including death for the patients and the 
public (1). However, driving restrictions vary between countries and jurisdictions from no 
restriction to 10 years for commercial drivers (11).  
Other social effects of epilepsy include unemployment, a decrease in the quality of life and 
stigma. Patients with a diagnosis of epilepsy also face mental health issues such as depression, 
anxiety, and impairment of cognition and memory (15).  
For the purpose of this review, the word “seizure” is used to indicate an epileptic seizure.  
2.2 Epidemiology of the first unprovoked seizure 
Information about the incidence of the first single unprovoked seizures (FSUS) in 
developed countries comes from studies with prolonged follow-up times. In these studies, the 
cumulative incidence of single and recurrent epileptic seizures by the age of 80 years is 8% (16). 
Based on this information, 8% of individuals in a population will experience a single unprovoked 




men and at the extremes of ages, i.e. children less than a year of age and individuals older than 
65years (16).  
The diagnosis of unprovoked seizures results in an increase in mortality among young 
children and the elderly compared to the general population (16). 
2.3 Prognostic outcome of a first unprovoked seizure 
Since the presence of a second unprovoked seizure is essential for the diagnosis of epilepsy, 
accurate knowledge about the risk of recurrent seizures after a FSUS is critical. In general, the risk 
of recurrent seizures in adults in the two years following the diagnosis of FSUS is between 21% 
and 45%. However, this percentage changes with age at diagnosis. In the pediatric population, the 
risk of the seizure recurrence is between 37 and 60% in the first three years following the  FSUS 
(17). Meanwhile, in elderly patients, the likelihood of a second seizure one year after FSUS is 
between 45 and 62%.(18). Recurrences generally occur in the six months following a first seizure 
in 50% of patients and by two years in 80% of patients (19–21).  
Because of the possibility, but not certainty, of seizure recurrence, the main clinical 
decision is whether to treat or not treat patients presenting with a FSUS to avoid future seizures. 
This question has been addressed by randomized clinical trials which have included children and 
adults, showing that although the treatment with antiseizure medication (ASM) reduces 
recurrences, the use of ASM does not change long-term outcomes (22–25). 
2.3 Current diagnostic approach for patients presenting with a FSUS 
The main objective of assessing patients with FSUS is to establish an accurate and timely 




critical factors that will lead to evidence-based treatment decisions (27), potentially avoiding 
unnecessary stress and treatment with ASM. 
The typical patient who presents with a FSUS and seeks medical attention has suffered a 
generalized tonic-clonic seizure or focal onset seizure with secondary generalization (20). The 
clinical approach to these patients includes careful evaluation with differential diagnosis 
incorporating diagnostic test studies. As the approach and symptomatology of patients with FSUS 
among children differ from those in the adult population, the following review is based on the 
adults and the elderly.  
In the adult population, the clinical evaluation initially includes confirming the epileptic 
nature of the event through history and physical examination (28). In the gathering of the history, 
it is vital to recognize and search for predisposing factors such as family history of seizures or 
epilepsy, cognitive and developmental deficits, history of conventional risk factors such as a 
history of brain injury, stroke, Central Nervous System (CNS) infections, febrile seizures; and 
triggers such as toxins, sleep deprivation, flashing lights, and hyperventilation. The clinician must 
also take a detailed survey of signs and symptoms previous to the event such as aura (vision of 
lights or colour, epigastric rising sensation), behavioural changes (behavioural arrest, 
unresponsiveness or period of confusion), automatisms (pill-rolling, picking, lip-smacking), 
tiredness, and irritability (28). The next step is to collect a thorough descriptive seizure history, 
including order of appearance and duration of every component(including the presence of 
nocturnal seizures), level of consciousness, motor activity (clonic, tonic, tonic-clonic), sensory 
abnormality, predominant side of occurrence of each component, vocal output (cries, grunts) 
stereotypical facial expression (facial slackening, eyelid fluttering, staring or eye deviation) 




of tone, and tongue biting (28). It is also essential to gather information about signs and symptoms 
after the seizures, such as sleepiness, amnesia, confusion, headache, partial paralysis, muscular 
pain, behavioural changes, and injuries secondary to the seizure episode (28). 
Based on data from diverse, prospective studies, the presence of primary brain lesions or 
insults causing seizures ( remote symptomatic etiology) and the presence of nocturnal seizures 
have been found to increase seizure recurrence from 2.5 to 2.1 times for at 1 to 5 years respectively, 
following the presence of FSUS (29). Among the differential diagnoses that have to be considered 
are syncope, psychogenic nonepileptic events, hyperventilation, migraine, panic attack, transient 
global amnesia, and transient ischemic attack (30). 
Standard evaluation of adults with FSUS includes the use of medical imaging such as 1.5 
Teslas Magnetic resonance imaging (MRI) and Computed tomography (CT) scan. There is 
consistent evidence showing that the seizure recurrence is higher in patients with significant MRI 
lesions like dysplasias, leukomalacia/gliosis, encephalomalacia, any gray matter lesion, mass 
lesion, hemorrhage, vascular lesion, hippocampal abnormality, ventricular enlargement greater 
than 1.5 cm, or prominence of extra-axial fluid spaces greater than 1.0 cm (3,29,31). However, 
only 10% of the patients with SUS have CT or MRI lesions (3). 
2.4. The electroencephalogram as a diagnostic test in the assessment of a patient presenting 
with FSUS 
The gold standard of neurophysiology studies used in evaluating a patient with SUS is the 
electroencephalogram (EEG). The American Academy of Neurology recommends using EEG in 
children and adults after the presence of a FSUS based on evidence that the presence of 
epileptiform abnormalities will double the risk of seizure recurrence (3). Furthermore, the most 




a SUS if there is evidence to suggest that the risk of recurrence is higher than 60% (32), and the 
presence of ED in the rEEG increases the risk of further seizure by 60%. 
The rEEG in the assessment of patients with FSUS may help for several reasons. Firstly, 
EEG abnormalities contribute to characterized seizure type and potential epilepsy syndrome. 
Secondly, in specific cases, the EEG may detect subtle seizures, including absence, myoclonic, or 
partial seizures. Thirdly, specific EEG patterns may detect the presence of a focal cerebral lesion. 
Lastly and most importantly (33), the detection of Epileptiform Discharge (ED) is predictive of 
seizure recurrence (31).  
However, there are differences in opinions about the effect of timing, frequency, use of 
specific techniques such as sleep deprivation, and length of EEG on the increased likelihood of 
finding ED on the EEG. 
In general, the research on the role of EEG on the seizure recurrence on FSUS has been 
based on routine EEG within 2 to 10 days after FSUS (34–36).  
The routine EEG is a brief (usually 20-40 minutes ) and noninvasive test that records the 
brain's spontaneous electrical activity through scalp electrodes attached to a recording machine 
(37). These electrodes are placed by trained technologists using international standards. Some 
technical requirements to ensure a good quality clinical EEG recording must be satisfied (37). 
These requirements include electrode type, electrode placement, electrode impedance, number of 
recording channels, montages, sensitivity, filters, calibration, paper speed, length of the recording, 
hyperventilation, and photic stimulation (37). 
The EEG has been used since 1875 when the English physician named Richard Caton 




than one hundred years later, in 1929, German physiologist and psychiatrist Hans Berg recorded 
the first human EEG. In 1935, Gibbs and associates (1935) described patterns in the EEG related 
to epilepsy. Since then, numerous advances have occurred, ranging from multiple-channel EEG 
recording to digital EEG (38).  
  
2.5 Conundrums of the routine electroencephalogram  
The role of EEG on seizure recurrence has been well recognized. However, rEEG has its 
limitations.  
A recent metaanalysis of the literature aiming to ascertain the accuracy of the rEEG after a 
FSUS found that in adults, the sensitivity and specificity of epileptiform discharge for seizure 
recurrence of rEEG were 17.3% (95%CI: 7.9, 33.8%) and 94.7% (95%CI:73.7,99.1), respectively. 
These results resulted in a Positive Predicted Value (PPV) of 77% and a Negative Predicted Value 
(NPV) of 47% (4). Although the use of EEG improves the determination of recurrence risk after a 
FSUS compared with only the clinical diagnosis, it is not perfect. This situation has incited the 
development of tools with higher sensitivity and specificity. 
One factor potentially improving the ability to detect epileptiform abnormality is the timing 
of a routine EEG after a FSUS. The hypothesis behind this idea is that a routine EEG (rEEG) 
performed shortly after the seizure occurrence should provide more accurate information about 
EEG abnormalities. There is little research data directly comparing early and late EEG. King et al. 
in a prospective study assessing early EEG(within 24hrs of a seizure) and late EEG on 300 
pediatric and adult patients with first seizure, found that early EEG (within 24hrs) was more useful 




practical realities pose various logistic problems in obtaining an early EEG in emergencies and 
emergency rooms (ER) (5). 
Another factor potentially improving the accuracy of the rEEG assessment for epileptiform 
activity after the FSUS is a repetition of the rEEG regardless of the timing. Salinsky et al. 
retrospectively reviewed 1,201 rEEGs from 429 adults with an epilepsy diagnosis. They found that 
abnormalities, which included ED, were observed in 50% of patients in the first EEG, 84% by the 
third EEG, and 92% by the fourth independent rEEG (40). Similarly, in a prospective study, Baldin 
et al. found that in patients with SUS, the epileptiform abnormalities were present in 39% of cases 
after the first rEEG and 68% of the cases after the third rEEG (41). However, the repeated rEEG 
approach is associated with similar problems inherent as the single rEEG, such as the length of 
recording and exclusion of sleep samples. Furthermore, there is insufficient evidence about the 
economic impact and the advantages of series of rEEG vs. one rEEG.  
Another factor potentially improving the rEEG assessment's accuracy is the inclusion of 
sleep deprivation and the inclusion of the individual’s sleep cycle. Sleep deprivation is a method 
frequently used for inducing epileptiform activity in individuals with predisposition factors (37). 
Research has shown that the repeated EEG with the use of sleep deprivation compared with the 
first rEEG in individuals with the first unprovoked seizure (FSUS) increased the findings of 
epileptiform abnormalities from a yield of 43% to 61% (39). The problem with sleep deprivation 
is that this method is quite challenging to carry out, as individuals must be awake for more than 
20 hrs, which might even be traumatic for some patients (37). 
Finally, another factor that may affect the accuracy of the EEG is the length of the study. 




(VEEG) is the synchronous recording and display of EEG patterns and video-recorded clinical 
behaviour. Recording of 24hrs or more is generally done in a hospital inpatient setting in the 
Epilepsy Monitoring Unit. VEEG is the gold standard in the identification of localization and type 
of seizures in patients with epilepsy. The study of the use of VEEG in FSUS by Chen et al. has 
shown that the presence of epileptiform discharge increases the risk of seizure recurrence by 2.8  
times compared with the absence of epileptiform discharge (42). Also, Chen’s study showed that 
of 134 patients with FSUS, 43.3% (58 patients) had normal VEEGs, and 47.7% (76 patients) had 
abnormal VEEGs, although, with the later abnormal group, only 73.7 % had ED abnormalities. 
Patients presenting with a SUS and ED on the VEEG had a 2.84 times higher increased risk of 
seizure recurrence (42). 
In the final analysis, we may conclude that the best EEG modality to evaluate epileptiform 
activity in patients with FSUS is to use the EEG in the first 72hrs, with at least four EEGs after the 
index event, the use of EEG during sleep and finally, prolonged recording.  
A modality of EEG that may combine some of the best factors in the accurate evaluation 
of ED in patients with FSUS, including prolonged recording (up to 96 hrs) and the inclusion of 
sleep cycle, is the ambulatory EEG (6). Not only is the Ambulatory EEG comparable to the 
inpatient VEEG, but it also results in a 65% lower cost than VEEG (6) and does not require the 
use of inpatient services. 
The use of ambulatory EEG has been previously evaluated in patients with an established 




The study by Dash et al. prospectively evaluated the yield of ambulatory EEG for 
diagnosis, syndromic classification, and management of epilepsy. The researchers showed that a 
diagnostic yield of the ambulatory EEG was 72% to confirm the diagnosis of epilepsy (9).  
Another study evaluating the clinical utility of ambulatory EEG is the study of Liporace et 
al. In this study, the ambulatory EEG was compared with sleep-deprived EEG and a rEEG in 46 
patients with a previous diagnosis of epilepsy. This study showed that the ambulatory EEG and 
sleep-deprived EEG improved detection of epileptiform discharges by a similar amount (24% vs. 
33%). However, the ambulatory EEG detected seizures in 15% of the patients missed by the sleep-
deprived EEG (43). 
In 2016, Keezer et al. prospectively examined 72 individuals with diagnostic of epilepsy 
who were referred to the EEG laboratory as part of their regular medical care. The ambulatory 
EEG (23 hrs) was compared with a simultaneous rEEG, with authors reporting that the sensitivity 
of the ambulatory EEG was 2.23 times greater than the rEEG for ED. Furthermore, 25% of 
ambulatory EEG recorded epileptic seizures, which had been missed by the routine EEG (44). 
2.6 Discriminative power of a diagnostic test 
Most of the studies evaluating different EEG modalities have used the sensitivity and 
specificity, or diagnostic yield, also called positive predictive value (PPV). PPV is defined as the 
proportion of people with positive test results who have the disease (45). The predictive value is 
determined by the test's sensitivity and specificity and the prevalence of the disease. The 
dependence on the prevalence of the disease means that the test's usefulness for an individual 
patient changes with the prevalence of the disease in the population being tested (45). For instance, 




On the other hand, sensitivity and specificity are independent of the disease prevalence but 
affected by the disease severity. In the early stages of the disease, as in FSUS, it is difficult to 
establish a definitive diagnosis (46). It is, therefore, preferable to use likelihood ratios (LR). The 
LR is calculated using both sensitivity and specificity and is defined as the ratio between the 
probability of observing results in a patient with the disease in question and the probability of that 
result in a patient without the condition (47). 
Other methodological problems have included both the reliance on rEEG archived data 
(which is frequently inaccurate, incomplete, and retrospective) as the source of clinical information 
of the target population and the scarcity of prospective studies.  
To date, there is a shortage of research evaluating the ambulatory EEG in patients with 
FSUS and, particularly, the use of ambulatory EEG in the seizure recurrence. 
2.7 Thesis Contributions 
This dissertation makes an important contribution to the Clinical Neurology field, 
particularly to the diagnosis of patients with new-onset of seizure disorders and epilepsy. The 
primary purposes of this dissertation were to test the following hypotheses: 
1. The ambulatory EEG's discriminative power to detect ED in patients who present with 
FSUS will be comparable to measures reported in the literature for ambulatory EEG and epilepsy 
(within the range of 75-80%). 
2.The sensitivity, PPV and LR for detecting an ED will be better with ambulatory EEG in 




3. The likelihood of seizure recurrence after 52 weeks (one year) of follow-up in a patient 
who presents with a FSUS will be more than 50%. Also crucial to one-year seizure recurrence will 
be age, history of brain lesions, stroke and psychiatric comorbidity, presence of nocturnal seizures, 
and MRI or CT abnormalities. 
4.The presence of ED in the ambulatory EEG will be a predictor of seizure recurrence 
within a year's follow-up. 
It should be noted that it is not possible to prove the correctness or falsehood of these 
hypotheses formally. Instead, this dissertation was limited to provide high-quality evidence for or 
against their validity. It does so by crafting a prospective study and using STARD that is the 
standard for reporting diagnostic accuracy studies. As a new modality of EEG, the ambulatory 
EEG has been suggested by several authors as a promised alternative to other modalities of routine 
EEG but without a sufficient quality research complement. The use of Ambulatory EEG offers 
two main advantages over the routine EEG in the detection of ED’s including prolonged recording 
and inclusion of a sleep sample during the recording. Furthermore, the inclusion of the follow-up 
time in patients for a seizure recurrence and their relation to the presence of ED in the Ambulatory 





CHAPTER 3: THEORETICAL PERSPECTIVES 
This chapter will explain three underlying theoretical perspectives that will guide this 
research. The first is the clinimetrics framework, which provides the intellectual basis for clinical 
phenomena. According to Alvan R Feinstein, “clinimetrics concerns itself with indexes, rating 
scales, and other expressions that are used to describe or measure symptoms, physical signs, and 
other distinctly clinical phenomena in clinical medicine” (48).  
The second theoretical perspective involved in this research is the conceptual model 
developed by the Committee on Diagnostic Error in Health Care that has defined diagnostic error 
and illustrated the diagnostic process, the environment in which this process occurs, and the 
outcomes that result from this process (26). This conceptual model overlaps with the clinimetrics 
framework, providing a unified approach.  
The last perspective is the validity theory. The validity theory focuses on the clinical test 
and how it performs. 
3.1 From clinical observations to diagnosis.  
3.1.1 Clinimetrics. 
In a clinical setting, a diagnosis represents an individual's attribute that separates him/her 
from others (healthy vs. disease). Furthermore, a specific diagnosis suggests that this individual’s 
outcome will be different (death, accidents, complications, etc.) from that of others; may indicate 
that the person might be a candidate for treatment; or that his/her life will change following the 




3.1.2 Clinical observation and diagnosis 
The diagnostic process is a complex enterprise that involves information gathering and 
clinical reasoning to determine a patient’s health problem (26). This process happens over time 
and within the context of a health care system which may also affect the diagnostic process. 
The diagnostic process happens as follows: first, the patient becomes aware of a medical 
issue and connects with the health care system. Once the assessment has been organized, and the 
patient is connected with the assessor,  the bedside clinimetrics starts with an iterative procedure 
of data gathering, information integration and interpretation to determine a working diagnosis and 
ends by categorizing this diagnosis into a defined clinical entity (49). Taking a clinical history, and 
interviewing the family, conducting a physical exam, performing diagnostic testing or referring to 
another specialist are included in the process of data gathering. The information-gathering 
approach can be used at different times, and diagnostic information can be obtained differently. 
The continuous data-gathering procedure, incorporation of new information, and interpretation 
involve hypothesis generation and updating of prior probabilities over time (26). A single working 
diagnosis might be identified, but clinicians might still be working with several diagnoses, 
generally referred to as the differential diagnosis. It is most common that clinicians will consider 
more than one diagnostic hypothesis to explain the patient's symptoms, and he/she will refine this 
hypothesis as data is acquired in the diagnosis process (26). As a diagnostic method proceeds and 
the list of potential diagnoses becomes narrowed, diagnostic refinement of the working diagnosis 
becomes subject to analytic verification, in which the lead diagnosis is verified for its adequacy in 
clarifying the signs and symptoms, its coherency with the patient’s unique circumstances 
(physiology, risk factors), and whether a particular diagnosis is appropriate. When considering 




diagnostic method's validity one of the critical steps that must be recognized and taken into account 
in diagnosis making (49). 
3.2 Diagnostic error 
Getting the correct diagnosis is a crucial aspect of health care. However, this endeavor is 
far from perfect. Diagnostic error – inaccurate or delayed diagnosis- affects approximately 5% of 
U.S. adults who seek outpatient care each year. Furthermore, postmortem examination research 
has shown that diagnostic errors contribute to 10% of deaths, and diagnostic errors are the most 
common reason for paid medical malpractice claims (26). The Committee on Diagnostic Error in 
Health Care 2015 concluded that “most people will experience at least one diagnostic error in 
their lifetime,” calling for several changes, including an improvement in the diagnosis process, 
making the diagnosis a collaborative effort, including the patient in the diagnosis process, and 
improving the measurements of disease (26). All these factors are integral to the conceptual model 







Figure 3.1. The figure was taken from the book National Academies of Sciences, 
Engineering, and Medicine 2015. Improving Diagnosis in Health Care. Washington, 





3.3 Validity theory: Qualitative diagnosis and its validity 
Validity refers to “the degree to which evidence and theory support the interpretations of 
the test results for the proposed uses of the test.” Validity has five essential points (50): 
1. Tests are not valid or invalid, but the inferences and applications of the test are more 
or less valid 
2. Validity is an evaluative judgment of the degree to which empirical evidence and 
theoretical rationales support the adequacy and appropriateness of interpretations and 
actions based on test scores or other modes of assessment  
3. Validity is a unitary concept. Interpretation of the scores must be supported by evidence 
and/ or theory  
4. Each interpretation of a test must be supported logically and empirically. 
5. Each use of a test must be supported. 
In clinical settings, the term diagnostic test may incorporate at least one clinical observation 
prompting the diagnosis (such as an epileptic seizure). It may also include a set of findings during 
the history taking and examination (such as tongue biting and urine incontinence) or any 
paraclinical procedure (EEG with epileptiform discharge) (49). The degree to which a diagnostic 
test measures what it is intended to measure is called validity. A diagnostic test's validity has two 
essential aspects: internal validity and external validity (49).  
Internal validity is the diagnostic test's capacity to accurately recognize individuals with 
the disease and individuals without the condition than reference methods (biopsy, autopsy). The 
internal validity is assessed with the discriminative power and the clinical predictive value tests 




On the other hand, external validity is the diagnostic test's capacity to yield comparable 
results for different populations, different settings, different users, and different conditions. The 




CHAPTER 4: METHODS 
4.1 Study design  
This study is a prospective cohort study with a one-year (52 weeks) follow-up. A purposive 
sample of patients was recruited until the required sample size was reached. Patients were 
contacted a year after the FSUS through the Single Seizure Clinic (SSC).  
4.1.1 Study Population 
During October 2014 and December 2018, adult patients (>16 years old) referred to the 
SSC who experienced the first episode of an epileptic seizure and for which a SUS was clinically 
corroborated were consecutively invited to participate in this prospective study. The 
epileptologist/neurologist introduced the purpose of the research and implications (i.e., repeat 
EEG and 24 hrs. ambulatory EEG) of being a participant in this study. After a signed consent, 
patients were booked for repeat EEG (second rEEG) and ambulatory EEG on the next available 
date. 
4.2.1 Single Seizure Clinic and protocol 
The Single Seizure Clinic (SSC) is localized at the Royal University Hospital in Saskatoon, 
SK, Canada. The SSC started in 2011 and is the only available clinic that provides urgent 
assessment and evaluation of possible seizure episodes in an ambulatory setting to expedite the 
epileptologist/neurologist assessment. The SSC accepts referrals from physicians and health 
providers in the province. The referrals are triaged by a specialized nurse, who books the day and 
time for the morning first routine EEG (rEEG) and same-day afternoon initial consultation. 
4.2.2 Clinical diagnosis and diagnostic evaluation 
At the initial consultation, the patient first meets with the SSC nurse, who, after an 




epileptologist/neurologist. Afterwards, the epileptologist/neurologist performs a detailed clinical 
history of the patient, a detailed description of the seizure and peri-ictal events, and any collateral 
information, including a history of any previous auras, absences, or myoclonic jerks. Finally, the 
epileptologist/neurologist performs a neurological examination and reviews previous exams (CT, 
blood work, etc.) By this time, the results of the patient’s first rEEG were accessible to the 
epileptologist/neurologist. Based on their evaluation, the epileptologist/neurologist confirms that 
the patient had had an epileptic seizure, provides the diagnosis at the end of the consultation, and 
initiates treatment with anti-epileptic drugs (ASM) if seizure recurrence is highly likely (i.e., ED 
on rEEG or ambulatory EEG) or arranges for follow-up without medication as appropriate. For 
this study's purpose, further investigations were requested (i.e., second rEEG, and ambulatory 
EEG). A second appointment was scheduled to review the investigations' results if there were any 
abnormalities.  
According to the clinical information, the EEG (routine/ambulatory) and neuroimaging 
results, classification of generalized, focal, and unknown epilepsy was recorded for each case. 
All patients were followed or contacted through the SSC at one year following the FSUS.  
 
4.2.2.1 Electroencephalograms 
Upon study enrollment, a second rEEG and ambulatory EEG were arranged.  
The ambulatory EEG was recorded using 24 AC channels with four differential and four 
auxiliary DC channels capable of continuous recording (XLTEK Trex Ambulatory System). EEG 
10-mm diameter, gold-plated cup electrodes with a 2-mm center hole were attached to the scalp 
with collodion, according to the international 10-20 system and secured using a 4x4-8 ply gauze 




ensure electrode placement. An “event” button was attached to the system, permitting an indicator 
of the patient’s event, which was marked on the EEG recording at the specific time of pressing 
the event button. Patients were instructed to press the event button for all their events, including 
any auras or spells. Patients and family members documented events further with a written diary 
detailing each event's specific time, clinical description, and duration.  
The second rEEG was recorded before starting the recording of the ambulatory EEG using 
the same wrapping. Both standardized routine EEG, first and second, were recorded for 20 min 
following standard recommendations, including photic stimulation and hyperventilation. For the 
photic stimulation protocol, the stimulus was applied during closed and opened eyes. The 
frequency of photic stimulation increased from 2 to 60 Hz. Hyperventilation was achieved by 
asking the patient to breathe deeply for 3 minutes. 
After the setup and second routine EEG recording were finished, the patient was sent home 
with the ambulatory EEG in place with a diary and instructions to come back the next day (24 
hours recording) to end the recording. 
Findings were classified into two groups a) Epileptiform records showed generalized 
spikes and waves discharge, or focal spikes or sharp waves followed by slow waves. b) Records 
with abnormal slow activity and no associated epileptiform features were coded as abnormal but 
non-epileptiform. Only records with epileptiform activity (ictal or interictal) during the study 
period were considered as diagnostic. 
4.2.2.2 Standards for accepted care 
All the EEGs were performed under the accepted standards for electroencephalography in 
Canada (51). Specifically, all electrode impedances were equal and not exceeding 5000 Ω (ohms) 




readers were licensed neurologists recognized by the Royal College of Physicians and Surgeons 
of Canada and fully accredited by the Canadian Society of Clinical Neurophysiologists. 
4.3 Inclusion and exclusion criteria 
Eligible patients were at least 16 years of age, had a suspected single unprovoked seizure, 
and had been referred to the SSC for assessment. Patients were not eligible if 1) they had more 
than two events, 2) the initial assessment concluded that the event was not FSUS, 3) they had a 
previous diagnosis of epilepsy, and 4) if the first seizure was provoked or presented with status 
epilepticus. 
The first single seizure (FSUS) was defined according to the International League against 
Epilepsy as a “first transient occurrence of signs and/or symptoms due to abnormal excessive or 
synchronous neuronal activity in the brain, in the absence of an identified proximate precipitant 
factors” (6) or an event of loss of consciousness with signs and symptoms of an epileptic seizure. 
All eligible patients were invited to participate in the study and asked for written consent.  
4.4 Data collection 
4.4.1 Clinical and demographic information 
The demographic information was taken from the standardized questionnaire use by the 
nurse at the SSC. The clinical information, including data of the SUS, the initial assessment, and 
date of the referral doctor, time of the initial assessment and impression by the epileptologist, 
results of MRI or CT scans, were gathered after the consent of the patient to participate in the 
study.  
4.4.2 Outcome variables 
There were two main outcomes and one secondary outcome. One of the main outcomes 




of an unprovoked seizure after FSUS. The association of risk factors with the recurrence of 
unprovoked seizures was measured in terms of hazard ratios and their 95% confidence intervals.  
The first main outcome variable to evaluate the diagnostic test was the clinical diagnosis 
of epilepsy. The diagnosis of epilepsy is a decision that each neurologist/epileptologist made based 
on the 2015 ILAE epilepsy definition (14) as follow:  
1. At least two unprovoked seizures occurring >24 h apart.  
2. One unprovoked seizure with additional features accompanied by circumstances 
that increase the possibility of a seizure recurrence, such as an epileptiform electroencephalogram 
(EEG) study or stroke lesion in an imaging study such as Magnetic Resonance Imaging (MRI) or 
Computed Tomography (CT)).  
3. Diagnosis of an epilepsy syndrome such as Dravet’s syndrome, childhood absence 
epilepsy, or juvenile myoclonic epilepsy. 
The second main outcome variable to determine risk factors was the recurrence of an 
unprovoked seizure after FSUS.  
Lastly, the secondary outcome was the “time in weeks until an individual presents with a 
subsequent seizure after the FSUS,” and it was evaluated at one year of follow-up through the 
SSC.  
4.4.3 Independent variables for the seizure recurrence 
Medical history: a family history (first degree family with epilepsy), history of traumatic 
brain injury, stroke, and prior neurological surgeries increase the risk of seizure recurrence (53). 
Age: Previous studies have shown that elderly patients have a 45% to 62% risk of seizure 




recurrence in the first three years following the diagnosis (17). We created two age groups, one 
including individuals between 17 and 60 years old and the second group with individuals older 
than 60 years old. This grouping was based on the literature (54–56) and the incidence of epilepsy 
in Saskatchewan (57). 
Sex: Male patients have a higher seizure recurrence than female patients 
Presence of nocturnal seizure: the presence of nocturnal seizures increases the risk of 
seizure recurrence up to 2.5 times compared with patients without nocturnal seizures (3). 
Brain lesion: the presence of prior brain lesion or insult on CT or MRI increases the risk 
of seizure recurrence up to 2.1 times (3).  
Developmental disabilities and delay: the presence of any developmental disabilities in an 
individual has been found to increase the risk for epilepsy. The prevalence of epilepsy in this 
group is around 30-50% and higher than the general population (58). 
Stroke: the presence of cerebral infarction increases the risk of epilepsy up to 17 times 
higher than the general population (59) 
Use of ASM: the use of ASM is associated with risk reduction of  seizure occurrence 
within the next 1-2 years not long-term remission in individuals with single or infrequent seizures 
(60). In this context is important to remember that the use of ASM was coded as positive if patients 
confirmed having taken the medication and the medication was not started after seizure recurrence 
or because of seizure recurrence. 
 
4.5 Sample Size 
The sample size was calculated for cohort studies using Epitools epidemiological 




(62) and assumed a relative risk of two with a confidence level of 95% and power of 80%. The 
total sample size was 80 patients. However, this number was increased by 15% for the multivariate 
analysis with the expectation of a RR between 0.5 and 2.0. As a result, a sample size of 94 patients 
would be adequate. 
4.6 Ethical considerations 
Ethical approval was obtained from the Biomedical Research Ethics Board at the 
University of Saskatchewan (#14-30). 
4.7 Data 
4.7.1 Data collection and data entry 
We established a permanent and secure storage system for all the original files, including 
results of EEGs, SSC notes (copies), and collection tools for each patient following ethics 
requirements. 
The data were entered into the Statistical Package for Social Sciences IBM@ SPSS 
statistics@ version 27. We used a double-data entry, followed up with a comparison to check for 
inconsistencies.  
4.8 Data analysis 
4.8.1 General statistics analysis considerations 
Statistical analysis was completed with Statistical Package Social Science (SPSS) Version 
27 (SPSS Inc. Armonk, NY: IBM Corp.) and Statistical Analysis System University Edition (SAS 
Institute Inc., Cary, NC, USA). Statistical significance was defined by an alpha level of 0.05. For 
each objective, descriptive analysis using frequencies and proportions for categorical variables 





4.8.2 Analysis for Purpose 1 and Purpose 2 
The main outcome for purpose1 and 2 was 1) the evaluation of the discriminative power 
and clinical predictive value of the ambulatory EEG (sensitivity, specificity, PPV, NPV, and LR) 
for epileptiform activity in patients presenting with a FSUS and 2) the assessment of the 
discriminative measures of the Ambulatory EEG compared with first and second rEEG. The 
Standards for Reporting of Diagnostic Accuracy (STARD) statements and guidelines were 
followed (63). 
The first step in calculating sensitivity, specificity, PPV and NPV was to make a 2 X 2 
table with patients allocated to groups according to the presence or absence of the outcome 
(clinical diagnosis of epilepsy) in columns and categories to test (first rEEG, second rEEG, and 
ambulatory EEG) in rows. 
Sensitivity (%) was defined as the proportion of subjects with the outcome who had a 
positive result. 
Specificity (%) was defined as the proportion of subjects without the outcome who had 
negative results. 
Positive Predictive Value (%) was defined as the proportion of subjects with a positive test 
result that had the outcome. 
Negative Predictive Value (%) was defined as the proportion of subjects with a negative 
test result who did not have the outcome (45).  
A corroborating nonparametric Area Under the Curve (AUC) analysis was also performed 




The likelihood ratio for a positive test (LR+) was defined as the probability of a subject 
with the outcome (clinical diagnosis of epilepsy) having a positive test divided by the probability 
of an individual without the outcome of having a positive test. 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑜𝑜 𝑃𝑃 𝑠𝑠𝑠𝑠𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑃𝑃 𝑤𝑤𝑃𝑃𝑃𝑃ℎ 𝑃𝑃ℎ𝑠𝑠 𝑃𝑃𝑠𝑠𝑃𝑃𝑠𝑠𝑃𝑃𝑜𝑜𝑠𝑠 ℎ𝑃𝑃𝑎𝑎𝑃𝑃𝑎𝑎𝑎𝑎 𝑃𝑃 𝑝𝑝𝑃𝑃𝑠𝑠𝑃𝑃𝑃𝑃𝑃𝑃𝑎𝑎𝑠𝑠 𝑃𝑃𝑠𝑠𝑠𝑠𝑃𝑃
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑜𝑜 𝑃𝑃 𝑠𝑠𝑠𝑠𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑃𝑃 𝑤𝑤𝑃𝑃𝑃𝑃ℎ𝑃𝑃𝑠𝑠𝑃𝑃 𝑃𝑃ℎ𝑠𝑠 𝑃𝑃𝑠𝑠𝑃𝑃𝑠𝑠𝑃𝑃𝑜𝑜𝑠𝑠 ℎ𝑃𝑃𝑎𝑎𝑃𝑃𝑎𝑎𝑎𝑎 𝑃𝑃 𝑝𝑝𝑃𝑃𝑠𝑠𝑃𝑃𝑃𝑃𝑃𝑃𝑎𝑎𝑠𝑠 𝑃𝑃𝑠𝑠𝑠𝑠𝑃𝑃
 
A LR+ greater than one meant that the positive test was more likely to occur in patients 
with the outcome of clinical diagnosis of epilepsy. LR+ less than one indicated that a positive test 
was less likely to occur in patients with the outcome than the patients without the outcome(47). 
The likelihood ratio for a negative test (LR-) was defined as the probability of a subject 
with the outcome of having a negative test divided by the probability of an individual without the 
outcome of having a negative test. 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑜𝑜 𝑃𝑃 𝑠𝑠𝑠𝑠𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑃𝑃 𝑤𝑤𝑃𝑃𝑃𝑃ℎ 𝑃𝑃ℎ𝑠𝑠 𝑃𝑃𝑠𝑠𝑃𝑃𝑠𝑠𝑃𝑃𝑜𝑜𝑠𝑠 ℎ𝑃𝑃𝑎𝑎𝑃𝑃𝑎𝑎𝑎𝑎 𝑃𝑃 𝑎𝑎𝑠𝑠𝑎𝑎𝑃𝑃𝑃𝑃𝑃𝑃𝑎𝑎𝑠𝑠 𝑃𝑃𝑠𝑠𝑠𝑠𝑃𝑃
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑜𝑜 𝑃𝑃 𝑠𝑠𝑠𝑠𝑃𝑃𝑠𝑠𝑠𝑠𝑠𝑠𝑃𝑃 𝑤𝑤𝑃𝑃𝑃𝑃ℎ𝑃𝑃𝑠𝑠𝑃𝑃 𝑃𝑃ℎ𝑠𝑠 𝑃𝑃𝑠𝑠𝑃𝑃𝑠𝑠𝑃𝑃𝑜𝑜𝑠𝑠 ℎ𝑃𝑃𝑎𝑎𝑃𝑃𝑎𝑎𝑎𝑎 𝑃𝑃 𝑎𝑎𝑠𝑠𝑎𝑎𝑃𝑃𝑃𝑃𝑃𝑃𝑎𝑎𝑠𝑠 𝑃𝑃𝑠𝑠𝑠𝑠𝑃𝑃
 
LR- greater than one meant that a negative test was more likely to occur in patients with 
the outcome than in patients without the outcome. LR- less than one meant that a negative test is 
less likely to occur in patients without the outcome (47). 
The Receiver Operating Characteristic (ROC) curves were constructed by plotting each 
test's sensitivity and specificity pair on a graph with the 1-specificity on the x-axis and sensitivity 
of the y-axis. The area under the curve (AUC) aimed to estimate the discriminative power of a 
test. The closer the curve followed the upper left-hand corner and the larger the area under the 
curve, the better the test was at discriminating between those with and without the outcome(64). 
The AUC has been used to assess discriminatory ability statistical methods, mathematical 
models, and diagnostic tests (64). Especially, Swets (65) showed that using the results of a signal 




corresponds to the probability of correctly identifying which of the two stimuli is “noise” and 
which is “signal plus noise.” When an investigator calculates AUC directly from a rating 
experiment, mathematically, he/she is reconstructing random pairs of images, one from a diseased 
individual and one from the normal individual, and using the reader’s separate rating of these two 
images to stimulate what the reader would have decided if these two images had in fact been 
presented together as a pair (64). More important, it has been recognized by Bamber (66) that this 
“probability of correctly ranking a (normal, abnormal) pair is hyperconnected with the quantity 
calculated in the Wilcoxon or Mann Whitney-U statistical test. 
Consequently, AUC and ROC curves are used to compare different imaging techniques, 
which have the advantage of combining graphic methods for obtaining a smoothed areas and a 
computational formula for its standard errors (67). 
 
4.8.3 Analysis for Purposes 3 and 4 
The main outcome for Purpose 3 and 4 was 1) to identify risk factors associated with 
seizure recurrence and 2) assess if the presence of epileptiform activity on the ambulatory EEG 
was associated with increased risk of seizure recurrence in patients who present with a FSUS after 
one year of follow-up (52 weeks). 
After 52 weeks (one year) of follow-up, descriptive and bivariate analyses were performed 
for the outcome (seizure recurrence) and each independent variable. We analyzed the data as a 
“first recurrent not competitive ” event (68). 
The cumulative risks of recurrence were determined by life-tables methods, with an event 




up in each individual. Therefore, the computed risk represents the risk of recurrence conditional 
on surviving seizure-free through the specified time (follow-up) interval.  
Univariable analysis (Kaplan-Meier survival curves) was used for each variable relates to 
the cumulative percent recurrence to the time after FSUS. 
For this dataset, it was assumed that all survival times were independent of each other; 
censoring occurred randomly and solely as right-censoring and, it was non-informative (69).  
The start time within the analysis was considered as the day (specific date) of the FSUS. 
The survival time was measured by weeks. The event was considered the “time in weeks until an 
individual presents with a seizure recurrence” The seizure recurrence was regarded as recurrence 
of unprovoked seizures during one-year follow-up. Censoring occurred for three reasons (68): 
1) the individual did not have any seizure recurrence during the study period 
2) the individual was lost to follow-up during the study period 
3) the individual was withdrawn from the study because of death or some other reason. 
The Cox Proportional Hazard (PH) model was used to estimate univariable and 
multivariable ratios for the association of ED on the Ambulatory EEG and other variables with 
the seizure recurrence in patients with FSUS. Strengths of association were assessed by hazard 
ratios (HR) and with 95% confidence interval (95%CI) and were considered significant when the 
95% confidence interval's bounds did not include unity. 
The modelling followed the next steps: 
Step 0: Descriptive statistics. Percentage, totals, medians with dispersion analysis was be 




Step 1: The Kaplan Meier method was used to calculate unadjusted survival probability. 
The log-rank test was used to compare survival curves. A univariable non-parametric survival 
model was used to identify predictors for the multivariable model based on a p-value < 0.25. 
Step 2: A multivariable Cox PH model was used for the adjusted analysis. A (full) model 
used for prediction purposes contained all predictors significant at p-value= <0.05 and any other 
variable of clinical importance. Then, a backward model selection method was used to eliminate 
any covariates that were not statistically significant (p-value= >0.05). 
Step 3: The PH assumption of the Cox PH model was examined by two methods: a) 
examining the significance of the interactive effect between time and covariates in the model and 
b) examining covariate-wise residuals (Schoenfeld residuals) (70). Schoenfeld residuals are one 
of the goodness of fit testing approaches for assessing the PH assumption. The residuals are 
defined for each predictor in the model and for every subject who has the event. The residuals are 
the observed value of the variable under study minus the weighted average of the same variable 
in the population under investigation still at risk at time t. The weights are each subject’s hazard. 
The idea behind the statistical test is that if the PH assumption holds for a particular covariate, 
then the Schoenfeld residuals for that covariate will not be related to survival time (71).  
Step 4: The final model with significant interactions and confounders was obtained. 
Confounders were investigated by measuring change between unadjusted and adjusted β 
values. To determine whether the confounding was present, we deemed significant a difference 
>20% change in β’s values. Interactions were investigated by measuring their statistical 
significance. To determine if the interaction was present, we deemed them significant if the p-




CHAPTER 5: RESULTS 
5.1 Population  
Among the 125 individuals invited to participate in the study from October 2014 through 
December 2018, 122 consented to participate. Of the 122 participants, 22 were eliminated due to 
exclusion criteria. Most excluded patients had syncope or provoked seizures as the first clinical 
diagnosis (fig 5.2). Thus, the study population comprised 100 patients with a clinical diagnosis of 
first unprovoked seizure, aged 17-82 years (mean 41.8, median 36.5) for whom a complete follow-
up of 52 weeks after FSUS was obtained (see Table 5.1).  
Of the 100 patients in the cohort, 58% were females, and 21% of these individuals were 
older than 60 years old. 
Also, 63% of the patients were referred to the SSC by the ER physician, 35% by a family 








Figure 5.2. Flow diagram for study diagnostic performance of the ambulatory EEG versus routine EEG and risk factors 
for seizure recurrence among individuals with first single unprovoked seizures.  
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5.2 Clinical diagnosis and follow-up  
The overall diagnosis of epilepsy based on the ILAE definition of epilepsy (14) was 54% 
(54 cases), although seizure recurrence was present only in 33 individuals. The final diagnoses for 
the patients in the cohort are listed in Table 5.2. A total of six individuals had incomplete follow-
up because the patient chose to terminate our follow-up contact.  
The diagnosis of epilepsy (based on clinical characteristics, first rEEG, and imaging before 
the ambulatory EEG) was made on thirteen patients. In only five cases was the ascertainment of 
ED consistent between the first rEEG and the ambulatory EEG. 
Among the 54 cases with a diagnosis of epilepsy, seizures were categorized as focal in 31 
individuals (57%), generalized seizures in 11 individuals (20.4%), unknown in 11 individuals 
(20.4%), and combined generalized and focal seizure in 1 individual (2%). The clinical diagnosis 
was based on clinical information, EEG, and imaging results. 
Among the 54 patients with a diagnosis of epilepsy, factors that may have increased the 
risk before the first unprovoked included: one individual with febrile seizures, eight individuals 
with head trauma (unconsciousness or amnesia lasting longer than 30 minutes, skull fractures, or 
intracranial bleeding), three individuals with a history of brain surgery, two individuals with 
cerebrovascular disease (stroke), seven with hypertension, three with history of brain tumor and 
three with history of brain surgery. We did not find individuals with a history of neonatal seizures, 
central nervous-systemic infection, asphyxia at birth, central nervous system abnormalities, or any 
developmental disability. In addition, there were ten individuals with psychiatric comorbidity and 






Table 5.2 Final diagnosis† among cohort individual with FSUS (n=100) 
Diagnosis No. (%) 
Epilepsy 
           Focal 
           Generalized 
           Unknown 







Single unprovoked seizure 38 (38%) 
Syncope 7(7%) 
 
Psychogenic non-epileptic seizures 
 
1(1%) 
†Final diagnosis after clinical assessment +imaging +EEG 
‡ Percentage among patients with epilepsy 
 
 
The treating epileptologist/neurologist recommended initiation of ASM in 52 individuals 
(52/54) at their FSUS time, but only 45 individuals took the medication. The main reason for not 
taking the ASM among these individuals was personal (such as the use of marijuana, wanting to 
be pregnant, etc.). Among the ten individuals who were not taking ASM, nine had a seizure 
recurrence and of the 33 individuals who presented with seizure recurrence, 15 were already taking 
ASM. 
Lamotrigine was prescribed on 30 patients (57%), phenytoin on 13 patients (24.5%), 
clobazam in five patients (9.4%), levetiracetam in four patients (7.5%), and topiramate in one 
patient (2%). 
5.3 Wait times and time intervals 
The mean wait time for the first assessment after FSUS by an epileptologist/neurologist at 




and the ambulatory EEG was 12 weeks, and the time between the first routine EEG and 
ambulatory EEG was 1.6 weeks (see table 5.3). 
 
Table 5.3 Wait-times and time intervals for the cohort (n=100) 
Time between  Mean in weeks (SD) 
FSUS and 1st consult SSC 
FSUS and 1st rEEG 
FSUS and 2nd rEEG 
FSUS and Ambulatory EEG 
1st rEEG and ambulatory EEG 
 
9.94 (+ 7.2) 
9.94 (+ 7.2) 
12 (+ 1.6) 
12 (+ 1.6) 
1.6 (+3.7) 
FSUS= first single unprovoked seizure, rEEG=routine EEG 
 
5.4 Electroencephalograms analysis  
5.4.1 Discriminative Power of Ambulatory EEG 
A total of 100 individuals underwent the first rEGG, second rEEG and ambulatory EEG. 
There were no missing data or inconclusive results.  
The ability of the ambulatory EEG to identify individuals with the diagnosis of epilepsy 
(sensitivity) was 72%, compared with 11% of the first rEEG (p-value:< 0.001) and 22% of the 
second rEEG.  
The ambulatory EEG's ability to identify individuals without epilepsy (specificity) was not 
significantly different from the first rEEG nor the second rEEG (98% vs. 100% and 98%, 
respectively).  
With a prevalence of 54%, the ambulatory EEG's predictive ability to identify patients 
with a diagnosis of epilepsy (PPV) was 97% compared with 100% for the first and 92% for the 




epilepsy in individuals without ED findings (NPV) was 75% compared with 49% for the first 
rEEG and 52% for the second rEEG (see Table 5.4).  
In general, the global diagnostic accuracy of ambulatory EEG for detecting individuals 
with a diagnosis of epilepsy revealed an Area Under the Curve (AUC) of 0.85 (95%CI: 0.77, 0.93) 
for ambulatory EEG compared with 0.56 (95%CI: 0.44,0.67) for the first rEEG and 0.60 (95% CI: 






Table 5.4 Diagnostic Accuracy of different modalities of EEG for all patient with First Single Unprovoked Seizure with a 
clinical diagnosis of epilepsy (n=100) 
 First Routine EEG Second Routine EEG Ambulatory EEG 
 Epilepsy diagnosis Epilepsy diagnosis Epilepsy diagnosis 
Variable Positive Negative Positive Negative Positive Negative 
No. Abnormal test 6 0 12 1 39 1 
No. Normal test 48 46 42 45 15 45 
Total no. test 54 46 54 46 54 46 
Sensitivity (95% CI) 11 (4.5,23) 22(12,36) 72(58,83) 
Specificity(95%CI) 100 (89,100) 98(87,99.8) 98(87,100) 
PPV (95%CI) 100(52,100) 92(62,99.6) 97(85,100) 
NPV (95%CI) 49 (38,59) 52 (41,63) 75(62,85) 
LR (Positive [C])) Infinity 10(1.4,77.3) 33(4.7,232.5) 
LR (Negative [C]) 0.88(0.80,0.97) 0.8(0.7,0.9) 0.28(0.18,0.44) 
LR (Positive [W]) Infinity 12(1.8,79) 39 (5.6,270) 
LR(Negative[W]) 1(0.83,1.3) 0.91(0.71,1.2) 0.33(0.21,0.52) 
Prevalence 54%, PPV=positive predictive value; NPV=negative predictive value, LR w/prevalence=Likelihood ratio [C]=conventional, [W]=weighted by prevalence 
 
 
Table 5.5 Area Under the Curve (AUC) for the three competitive EEGs modalities among 100 individuals with FSUS to 
identify epileptiform discharges with a clinical diagnosis of epilepsy 




First routine EEG 









†Small 95%CI means that the model requires less input to provide a recommendation 





Figure 5.3 Receiver Operating Curves (ROC) based on three EEG modalities for 100 






5.4.2 Clinical predictive value of Ambulatory EEG 
The ambulatory EEG was 39 times more likely to show epileptiform discharge in 
individuals with a clinical diagnosis of epilepsy than in individuals without epilepsy (wLR+). On 
the other hand, the ambulatory EEG was 0.33 (67%) less likely to show an absence of epileptiform 
discharge in an individual with an epilepsy diagnosis than one without epilepsy (wLR-). (Table 
5.4).  
5.5 Seizure recurrence and associated risk factors- One-year outcome 
5.5.1 Overal risk of seizure recurrence-Life-table estimates  
Based on the lifetables results (Table 5.6) among individuals with FSUS, the seizure 
recurrence was estimated to be 21%, 30%, and 36% at 12, 24 and 52 weeks, respectively, following 
the first SUS. The estimated hazard function graph (Figure 5.5) shows that the recurrence rate 
increased to its highest in the 8th week after the FSUS (0.030). The recurrence rate decreases from 
the end of the 8th week to the 22nd second week (0.004). After the 22nd week, there is an increase 
of recurrence (0.014), no higher than the initial rate, after which the recurrence rate decreases again 





Table5.6 Life table of a cohort of individuals with FSUS (n=100) 
Interval in 
























Lower Upper     
0 4 5 0 1.00 0 
4 8 10 4 0.95 0.05 
8 12 5 4 0.84 0.15 
12 16 5 4 0.79 0.21 
16 20 2 2 0.74 0.26 
20 24 1 1 0.71 0.29 
24 28 3 2 0.70 0.30 
28 32 2 0 0.66 0.34 
32 36 0 1 0.64 0.36 
36 40 0 0 0.64 0.36 
40 44 0 2 0.64 0.36 
44 48 0 1 0.64 0.36 
48 52 0 0 0.64 0.36 
52 
 
. 0 46 0.64 0.36 
†ti: Time of follow-up on weeks.  
‡Survival function: Si is the unconditional probability of remaining free from further seizures. 𝑆𝑆𝑃𝑃 = 𝑃𝑃(𝑇𝑇 > 𝑃𝑃𝑃𝑃) = 𝜋𝜋 �1− 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑐𝑐𝑎𝑎 𝑎𝑎𝑡𝑡
𝑟𝑟𝑐𝑐𝑟𝑟𝑐𝑐𝑡𝑡𝑟𝑟𝑡𝑡𝑟𝑟𝑟𝑟 𝑡𝑡𝑟𝑟𝑖𝑖𝑡𝑡𝑖𝑖𝑡𝑡𝑖𝑖𝑖𝑖𝑐𝑐𝑖𝑖𝑐𝑐 𝑐𝑐𝑎𝑎 𝑎𝑎𝑡𝑡
� 
£ Failure function F(t) unconditional probability that a randomly selected individual from the population will have a seizure. 𝐹𝐹(𝑃𝑃) = Pr(𝑇𝑇 ≤ 𝑃𝑃) , 𝑃𝑃 ≥






Figure 4.5 Lifetable estimate of failure function for a cohort of patients with FSUS 
(n=100) 
Failure function F(t) is the unconditional probability that a randomly selected individual from the population will 
have further seizures. 𝐹𝐹(𝑃𝑃) = Pr(𝑇𝑇 ≤ 𝑃𝑃) , 𝑃𝑃 ≥ 0 = (1 − 𝑆𝑆𝑃𝑃) × 100 
 
 
5.5.2 Impact of risk factors and the presence of ED in the ambulatory EEG on seizure 
recurrence 
Among patients with FSUS, the presence of febrile seizures, psychiatric comorbidity, 
presence of nocturnal seizures, history of stroke, age group >60 years, use of ASM, and 
epileptiform activity on the ambulatory EEG were independently associated with a higher risk of 




Table 5.7 Bivariate analysis as estimated by log-rank and Cox regression of 
characteristics for demography and risk factors for seizure recurrence in the cohort of 
patients with First Single Unprovoked Seizure evaluated for the initial model† (n=100) 




HR (95%CI) † p-
value 
Age 17-60 0.49 0.74(0.3,1.8) 0.21M 
History of:     










Febrile seizures No 0.17 0.05 (0.0,38.3) 0.37 
Developmental delay No 0.24 0.05(0.0,107.4 0.44 
Head trauma No 0.53 0.74 (0.3,1.9) 0.53 
Psychiatric comorbidity No 0.26 0.62(0.27,1.43) 0.26 
Stroke No 0.00 5.69(1.33,24.39) 0.01 
Systemic hypertension No 0.80 0.86 (0.3,2.8) 0.80 
Tongue biting No 0.66 1.2 (0.6,2.4) 0.67 
Incontinence No 0.43 0.6(0.2,2) 0.44 
Confusion after event No 0.95 0.98 (0.5,2) 0.90 
Automatism/behavioral No 0.68 1.3 (0.39, 4.2) 0.68 
Nocturnal seizures No 0.44 1.36 (.61,3.0) 0.43 
Antiepileptic drug 
initiation 
No <0.001 12.78(6.03,27.09) <0.001 
CT/MRI Normal 0.88 0.91(0.4,2) 0.90 









† Bivariate hazard ratios (HR) estimated by Cox PH regression analysis for seizure recurrence at 52 weeks 
‡p-value based on the Log rank  
£ Epileptiform discharge 
 
 
Factors significant at < 0.25 as well as factors with known clinically significance were 
entered into the initial Cox Proportional Hazard Ratio model and tested for interaction, 
confounding, and PH assumptions. We found that older age group was a confounder in the 
association between ED in the ambulatory and seizure recurrence. However, the association 
between ED in the ambulatory EEG and seizure recurrence at 52 weeks remained significant when 
it was adjusted by age group. Older age was statistically positively correlated with the presence of 




shown in Table 5.8, Figure 5.6, and Figure 5.8, where unadjusted and adjusted β’s changed, and 
the explanatory model is described.  
We also found that the use of ASM was a confounder in the association between seizure 
recurrence and the presence of ED in the ambulatory EEG. However, the association between ED 
in the ambulatory EEG and seizure recurrence at 52 weeks remained statistically significant when 
was adjusted by the use of ASM. The use of ASM was statistically positively correlated with the 
presence of ED in the ambulatory EEG and statistically positively correlated with the seizure 
recurrence. 
These results from the final model show that at any point after FSUS and adjusted by age 
group and use of ASM, seizure recurrence occurred at 3.2 times (32%) higher rate in individuals 
with the presence of epileptiform discharge on the ambulatory EEG than individuals without ED 
on the ambulatory EEG.  
Similarly, at any point after FSUS and adjusted by age group and presence of ED in 
ambulatory EEG, the seizure recurrence occurred at a 12.8 times higher rate in individuals using 
ASM than individuals not using ASM. 
On the other hand, we found that at any point after a FSUS and adjusted by presence of 
ED on the ambulatory and the use of ASM, seizure recurrence in patients older than 60 years old 






Table 5.8 Unadjusted and adjusted Cox PH regression examining the association between ED in the ambulatory EEG and 
seizure recurrence adjusted by >60 years old age in 100 patients with FSUS  
 
A) Unadjusted       B) Adjusted 
 Seizure Recurrence 
 Crude model  
 βunadjusted HRunadjusted p-value 
ED in the 
ambulatory EEG 
  
1.090a 2.98a 0.002 
HR, Hazard Ratio 
 Unadjusted Model 
a. ℎ�𝑃𝑃𝑡𝑡(𝑃𝑃)� = ℎ0(𝑃𝑃) exp[𝛽𝛽1𝑨𝑨𝑨𝑨𝑨𝑨]             
         HR, Hazard Ratio 
         Adjusted Model 








 Seizure Recurrence 
 Adjusted model  
 βadjusted HRadjusted p-value 
ED in the ambulatory 
EEG  
 
1.38b 3.99b <0.001 
Patients >60 years of 
age b 
 






Table 5.9 Unadjusted and adjusted Cox PH regression examining the association between Epileptic Discharge in the 
ambulatory EEG and seizure recurrence adjusted by use of antiseizure medication in 100 patients with FSUS 
 
A) Unadjusted       B) Adjusted 
 Seizure Recurrence 
 Crude model  
 βunadjusted HRunadjusted p-value 
ED in the 
ambulatory EEG 
  
1.090a 2.98a 0.002 
HR, Hazard Ratio 
  Unadjusted Model      
         HR, Hazard Ratio 
a. ℎ�𝑃𝑃𝑡𝑡(𝑃𝑃)� = ℎ0(𝑃𝑃) exp[𝛽𝛽1𝑨𝑨𝑨𝑨𝑨𝑨]             Adjusted Model 






 Seizure Recurrence 
 Adjusted model  
 βadjusted HRadjusted p-value 
ED in the ambulatory 
EEG  
 
0.69b 2.0b 0.06 
Use of ASM b 
 







Figure 5.5 A- Hazard function plot of the association between seizure recurrence and presence of epileptiform discharge in 
the ambulatory EEG stratified by age group among patients with FSUS (n=100) 
   B-C Kaplan-Meier plots assessing the association between seizure recurrence and the presence of epileptiform 








Figure 5.6  A- Hazard function plot of the association between seizure recurrence and presence of epileptiform 
discharge in the ambulatory EEG stratified by use of ASM among patients with FSUS (n=100) 
   B-C- Kaplan-Meier plots assessing the association between seizure recurrence and the presence of epileptiform 







Table 5.10 Final Cox Proportional Hazard model for risk factors of seizure recurrence 
in a cohort of individuals with FSUS (n=100) 
 
Risk Factors Category HR (95%CI) p-value 
Age 
 
>60 0.27(0.10,0.74) 0.010 
Use of ASM 
 
Yes 12.85(5.64, 29.27) <0.001 
Ambulatory 
EEG 
Presence of ED  3.17(1.47, 6.83) 0.003 
 
         No. of subjects=100. Log likelihood=216.597 





CHAPTER 6: DISCUSSION, CONCLUSIONS, AND RECOMMENDATIONS 
6.1 Discussion 
This research sought to advance knowledge in the field of diagnostic testing among 
individuals who present with FSUS by assessing the discriminative power and clinical predictive 
value of the use of ambulatory EEG for the detection of epileptiform discharge compared with the 
first and second rEEG. We also aimed to find the association between the presence of ED on the 
ambulatory EEG as a better strategy to forecast the seizure recurrence.  
As described in Chapter 2, routine EEG remains central in the diagnosis of epilepsy 
(further seizure recurrence) as the last definition of epilepsy by the ILAE includes the presence of 
a single unprovoked seizure plus the presence of epileptiform discharges in the routine EEG (32). 
However, as a diagnostic test, the rEEG has limited sensitivity (up to 17%) and depends on when 
and how frequently it is administered.  
Although numerous studies have examined several methods aiming to predict the seizure 
recurrence in individuals with FSUS, few gains have been made to improve these efforts. 
Consequently, little has occurred to advance our knowledge in this field (73). 
An alternative method presented here is the use of Ambulatory EEG. This method offers 
excellent convenience, low cost, improved access, greater sampling of natural sleep and circadian 
rhythms, and better diagnostic yield for identification, classification and localization of seizures 





6.1.1 Discriminative power and clinical predictive value of the Ambulatory EEG 
In the present study, we found that the ambulatory EEG had a significantly better 
sensitivity, improved NPV and, as a whole, was a better diagnostic test to detect ED than the first 
and second rEEG among individuals who presented with FSUS.  
Our results are understandable in light of the technical advantages of ambulatory EEG over 
routine EEGs. With the ambulatory EEG, a greater sampling of natural sleep and circadian rhythms 
and longer recording time are advantages. Furthermore, most ambulatory EEG systems are light 
and easy to use (52).  
On the other hand, historically, a serious problem with ambulatory EEG has been the 
presence of artifacts. Artifacts are present in all EEG recording modalities and are increasingly 
more likely as the span of the recording increments increases (52). However, novel techniques are 
evolving to avoid the most common types of artifacts during the ambulatory EEG’s recoding (52). 
Furthermore, the use of minimal standards to complete the electroencephalograms, such as 
minimal impedance limits of 5000 Ω, may decrease the frequency of artifacts. In this study, none 
of the completed electroencephalograms (routine and ambulatory) were inconclusive. 
Despite best efforts, one of the weaknesses of this study was the lack of reliability 
measures. Research has shown that inter-rater (agreement among raters) and intra-rater (individual 
agreement) reliability are generally low for EEG’s interpretation. Furthermore, kappa for intra-
rater reliability is better (range from 0.33 to 0.73) than inter-rater kappa (range of 0.29 to 0.62) of 
the EEG interpretation (75). Also, high confidence in interpretations among readers had low to 
moderate inter and interrater reliabilities. On the other hand, knowledge of the patient’s history, 




test, and technologist comments, increases both reliabilities. In this study, each reader knew the 
patient's history and performed the clinical assessment, making it difficult to make objective 
reliability measures. Moreover, the set of three EEG’s (first, second, and ambulatory) was 
interpreted by the same reader. As a whole, this situation simulates the reality of most of the 
neurology clinics around the world. 
Predicting seizure recurrence does not mean better management or prevention of further 
seizures, as it has shown in previous studies (3). Instead, this study aimed to decrease diagnostic 
errors, defined as “ the failure to establish accurately and in a timely fashion the health status of 
the individual and communicate effectively this to the patient” (26). The evidence supporting this 
view is given in Table 5.5. The number of ED detected by the ambulatory EEG and missed by the 
first and second routine EEGs was significant. These are precisely the individuals that may have 
adverse outcomes such as recurrence of multiple seizures or even death. 
6.1.2 Seizure recurrence after FSUS 
Several studies on the risk of seizure recurrence after FSUS, including two randomized 
clinical trials, have shown that among untreated individuals with ASM, 40-50% can expect a 
recurrence within two years of the index seizure (73).  
The seizure recurrence in this study was 36% at 52 weeks (one year) of follow-up. The 
frequency of seizure recurrence is consistent with previous studies with similar populations 
(76,77). Known predictors for the first recurrence were searched and found. For instance, the 
presence of ED in the EEG, age, history of febrile seizures, nocturnal seizures, psychiatric 
comorbidity, history of stroke, and use of ASM are important risk factors. However, age group, 




taking into account that the main purpose of this research was to find the association between the 
presence of ED in the ambulatory EEG and seizure recurrence. On the other hand, we did not find 
that other significant risk factors such as stroke, psychiatric comorbidity, febrile seizures, 
generalized seizures (vs. focal seizures), family history of epilepsy, brain trauma, and 
developmental delay were significant. We may explain this phenomenon as a result of the age 
groups analyzed and the purposes of this research. While previous studies have included children 
and adults, the current study included adults and elderly individuals(78). Some authors have 
already noted the lack of studies of seizure recurrence after FSUS that include the elderly 
population (>60 years of age) (18,78,79). In this cohort study there were 21 individuals older than 
60 years of age who were compared to the younger group (17-60 years of age). In the bivariate 
analysis, individuals older than 60 years old had a non-significant hazard ratio of 0.74(95%CI: 
0.3,1.8) for seizure recurrence, which is similar to the results of Lawn et al. (18), taking into 
account that this research had a follow-up of one year. However, in the multivariate analysis, we 
found that this variable was a confounder in the association between seizure recurrence and the 
presence of ED in the ambulatory EEG. This phenomenon is demonstrated statistically in Table 
5.8, showing changes between unadjusted and adjusted β’s (Figure 5.6 and Table 5.9) and 
discussed in the results section; thus, it should be controlled as we did in the Cox regression 
analysis. Furthermore, in the final Cox regression model, individuals older than 60 years were 
found to be statistically less likely to present seizure recurrence, which is a phenomenon seen 
previously in case-control and cohort studies addressing risk factors for seizure recurrence in an 
elderly population (18,54). Age as a confounder was supported as it fulfilled criteria for 
confounding as follows: a wide variety of normal and abnormal EEG patterns can be seen in 




of seizure recurrence among different age groups (16). Finally, its distribution across the exposure 
(ED in the ambulatory EEG) can not be determined by the exposure or by the outcome (seizure 
recurrence). 
Another confounder found was the use of ASM. This is likely the result of the current 
management of FSUS (surrogate variable). As research has shown, the use of ASM reduces the 
occurrence of seizures (60). Thus, when the individual is evaluated by the 
epileptologist/neurologist and the clinician considers the patient is at high risk of recurrence (ED 
in the ambulatory EEG), the clinician will prescribe ASM. Therefore, the use of ASM (surrogate 
variable) is associated with both ED in the ambulatory EEG and the seizure recurrence. However, 
this variable is considered incomplete confounding. The underlying explanatory structure under 
this confounding is that the use of ASM is associated with both ED in the ambulatory EEG and 
the seizure recurrence. Nevertheless, ED in the ambulatory EEG is also associated with seizure 
recurrence (72), see Table 5.9.  
The diagnosis of epilepsy in this study was similar to a previous cohort in the same SSC 
(62), reflecting a referral bias and highly skilled physicians making the diagnosis of epilepsy. We 
also believe that the use of the last practical definition of epilepsy in the presence of SUS plus 
EEG abnormalities (14) may have played a role in the high diagnosis of epilepsy. Another 
weakness of this study was the short follow-up time. The ideal study would include the ambulatory 
EEG after FSUS and follow-up to 5 years. With this follow-up, we could explore longer-term 
seizure recurrence in individuals with ED in the ambulatory EEG that did not present with seizure 
recurrence initially but were initiated on ASM (based on medical history and imaging) as it is well 






Figure 5.7 A diagram depicting the explanatory model of the association between the presence of epileptic discharge in the 







Figure 5.8 A diagram depicting the explanatory model of the association between the presence of epileptic discharge in the 








Figure 5.9 A diagram depicting the final model of the association between the presence of epileptic discharge in the 






This was a pragmatic, prospective, hospital-based clinical study comparing the worldwide 
gold standard for the diagnosis of epilepsy (first rEEG) and a frequently used modality of repeated 
rEEG (second EEG) with a low cost and longer recording modality of EEG (ambulatory EEG), 
finding an improved sensitivity and better negative predictive value for the ambulatory EEG than 
the first rEEG and second EEG. Overall, the ambulatory EEG was shown to be a better diagnostic 
test for the diagnosis of epilepsy than rEEG’s. In this research, we investigated known risk factors 
for seizure recurrence in individuals presenting with FSUS, such as stroke, febrile seizures, family 
history of epilepsy, and age group. We confirmed that the presence of ED was a significant factor 
in the presence of seizure recurrence at 52 weeks. However, the clinical evaluation of the patient 
by a specialist (epileptologist/neurologist) remains fundamental in assessing individuals with 
FSUS. Also, the use of ambulatory EEG can be used in high-income countries and in low-income 
countries around the world where specialized epilepsy units are not available and replacing then 
less accurate routine EEG. 
Further research with longer follow-up and population-based studies, including the 
pediatric population, will help clarify the ambulatory EEG's benefits in the general population. 
Moreover, future studies should control for and compare differences between specialist and non-
specialist assessments. 
Any effort to improve diagnostic test for the diagnosis of epilepsy will reduce diagnostic 
errors and reduce the social and psychological stress around newly epileptic individuals and their 
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